Sanguinetti Maurizio, Posteraro Brunella, Spanu Teresa, Ciccaglione Daniela, Romano Lucio, Fiori Barbara, Nicoletti Giuseppe, Zanetti Stefania, Fadda Giovanni
Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Rome, Italy.
J Clin Microbiol. 2003 Apr;41(4):1463-8. doi: 10.1128/JCM.41.4.1463-1468.2003.
Production of extended-spectrum beta-lactamases (ESBLs) is an important mechanism of beta-lactam resistance in Enterobacteriaceae: Identification of ESBLs based on phenotypic tests is the strategy most commonly used in clinical microbiology laboratories. The Phoenix ESBL test (BD Diagnostic Systems, Sparks, Md.) is a recently developed automated system for detection of ESBL-producing gram-negative bacteria. An algorithm based on phenotypic responses to a panel of cephalosporins (ceftazidime plus clavulanic acid, ceftazidime, cefotaxime plus clavulanic acid, cefpodoxime, and ceftriaxone plus clavulanic acid) was used to test 510 clinical isolates of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Providencia stuartii, Morganella morganii, Enterobacter aerogenes, Enterobacter cloacae, Serratia marcescens, Citrobacter freundii, and Citrobacter koseri. Of these isolates, 319 were identified as ESBL producers, and the remaining 191 were identified as non-ESBL producers based on the results of current phenotypic tests. Combined use of isoelectric focusing, PCR, and/or DNA sequencing demonstrated that 288 isolates possessed bla(TEM-1)- and/or bla(SHV-1)-derived genes, and 28 had a bla(CTX-M) gene. Among the 191 non-ESBL-producing isolates, 77 isolates produced an AmpC-type enzyme, 110 isolates possessed TEM-1, TEM-2, or SHV-1 beta-lactamases, and the remaining four isolates (all K. oxytoca strains) hyperproduced K1 chromosomal beta-lactamase. The Phoenix ESBL test system gave positive results for all the 319 ESBL-producing isolates and also for two of the four K1-hyperproducing isolates of K. oxytoca. Compared with the phenotypic tests and molecular analyses, the Phoenix system displayed 100% sensitivity and 98.9% specificity. These findings suggest that the Phoenix ESBL test can be a rapid and reliable method for laboratory detection of ESBL resistance in gram-negative bacteria.
产超广谱β-内酰胺酶(ESBLs)是肠杆菌科细菌对β-内酰胺类抗生素耐药的重要机制:基于表型试验鉴定ESBLs是临床微生物实验室最常用的策略。Phoenix ESBL试验(BD诊断系统公司,美国马里兰州斯帕克斯)是最近开发的一种用于检测产ESBL革兰阴性菌的自动化系统。采用一种基于对一组头孢菌素(头孢他啶加克拉维酸、头孢他啶、头孢噻肟加克拉维酸、头孢泊肟、头孢曲松加克拉维酸)表型反应的算法,对510株临床分离的大肠埃希菌、肺炎克雷伯菌、产酸克雷伯菌、奇异变形杆菌、斯氏普罗威登斯菌、摩根摩根菌、产气肠杆菌、阴沟肠杆菌、粘质沙雷菌、弗氏柠檬酸杆菌和科氏柠檬酸杆菌进行检测。根据目前表型试验结果,这些分离株中319株被鉴定为产ESBL菌,其余191株被鉴定为非产ESBL菌。等电聚焦、聚合酶链反应(PCR)和/或DNA测序联合应用显示,288株分离株携带bla(TEM-1)-和/或bla(SHV-1)-衍生基因,28株携带bla(CTX-M)基因。在191株非产ESBL分离株中,77株产生AmpC型酶,110株携带TEM-1、TEM-2或SHV-1β-内酰胺酶,其余4株(均为产酸克雷伯菌菌株)超量产生K1染色体β-内酰胺酶。Phoenix ESBL试验系统对所有319株产ESBL分离株以及4株产酸克雷伯菌K1超量产生菌株中的2株给出了阳性结果。与表型试验和分子分析相比,Phoenix系统显示出100%的敏感性和98.9%的特异性。这些结果表明,Phoenix ESBL试验可为革兰阴性菌中ESBL耐药性的实验室检测提供一种快速可靠的方法。